Heron Therapeutics Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Direxion Daily S&P 500 Bull 3X Shares trades at $270.91. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | SPXL | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.96 | $288.04 |
52-Week Low | $0.39 | $170.20 |
Enterprise Value | $189.36M | — |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
SPXL, a leveraged ETF tracking the S&P 500, trades at $264.57, down 0.44% on the day amid broader market weakness. Technical indicators signal a bearish bias with moving averages pointing lower, though oscillators remain neutral. Recent news highlights concerns about S&P 500 valuation and AI-driven concentration risks, with the index facing pressure from chip stock declines and macroeconomic uncertainty.
The outlook hinges on S&P 500 performance, with earnings season and economic data as key catalysts. Risks include market overvaluation and sector concentration, but analyst targets suggest potential upside if bullish forecasts materialize. Investors must weigh leveraged exposure against volatility and broader index trends.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →